Skip to main content
Livermore
Livermore
ZHEN

Tvardi Therapeutics, Inc.

TVRD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001346830

No open-market purchases or sales by Tvardi Therapeutics, Inc. insiders were filed in the last 90 days; 57 institutions reported holding it in 13F filings for Q2 2026, worth $4.24M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Tvardi Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Tvardi Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Tvardi Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Wyzga Michael SDirector–Jun 11, 20261
Shah SujalDirector–Jun 11, 20261
Smith CynthiaDirector–Jun 11, 20261
Hall Wallace L JrDirector202,044IndirectJun 11, 20261
Shiff Susan Ph.D.Director202,085Jun 11, 20261
Kauh John Saewook M.D.Chief Medical Officer–Feb 2, 20262
Alibhai Imran NizamudinChief Executive Officer–Feb 2, 20262
O'Brien Stephen PaulPrincipal Accounting Officer–Feb 2, 20262
Conn Avi DanielChief Financial Officer–Feb 2, 20262
Tweardy Samuel David10% Owner0IndirectAug 5, 20250
Wirk ShaheenDirector263,164IndirectMay 2, 20250
Larson Jeffrey LeroySVP, Research & Development–Apr 21, 20250
Chen YixinVP, Chem, Mfg and Ctrls–Apr 21, 20250
Terrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C.7,190Mar 4, 20250
Posner ChristopherPRESIDENT AND CEO13,109Mar 4, 20250
Vogelbaum MartinDirector411,007Jun 6, 20240
Ives Jeffrey L.Director198,485Jun 6, 20240
Boudreau Helen MDirector150,647Jun 6, 20240
von Moltke LisaDirector183,009Jun 6, 20240
Goncalves JoanaCHIEF MEDICAL OFFICER53,365Apr 9, 20240
Maynard Ryan DCHIEF FINANCIAL OFFICER8,012Feb 12, 20240
Menzaghi Frederique Ph.D.CHIEF SCIENTIFIC OFF,SVP-R&D167,247Feb 5, 20240
Bains Harrison M JrDirector57,438Jun 5, 20230
Makara RichardVP, Head of Accting;Controller13,583Jun 16, 20220
Reilly Thomas CharlesChief Financial Officer37,811Mar 4, 20220
Chalmers Derek TPresident & CEO991,405Sep 9, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 9, 2024 (view filing)Apr 54 daysTerrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C.SSale−2.75K$0.83−$2.28K−3.0%88.2K after
Apr 9, 2024 (view filing)Apr 54 daysGoncalves JoanaCHIEF MEDICAL OFFICERSSale−2.75K$0.83−$2.28K−4.9%53.4K after
May 6, 2024 (view filing)May 24 daysPosner ChristopherPRESIDENT AND CEOSSale−3.94K$0.75−$2.95K−2.2%176.6K after
Aug 2, 2024 (view filing)4:05 PM ETAug 11 dayPosner ChristopherPRESIDENT AND CEOSSale−4.15K$0.35−$1.45K−2.3%172.4K after
Nov 6, 2024 (view filing)4:51 PM ETNov 42 daysPosner ChristopherPRESIDENT AND CEOSSale−3.67K$0.29−$1.06K−2.1%168.8K after
Feb 6, 2025 (view filing)Feb 42 daysPosner ChristopherPRESIDENT AND CEOSSale−372$4.72−$1.76K−2.6%13.7K after
Mar 4, 2025 (view filing)Feb 284 daysTerrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C.SSale−163$4.76−$775.88−2.2%7.19K after
Mar 4, 2025 (view filing)Feb 284 daysPosner ChristopherPRESIDENT AND CEOSSale−583$4.75−$2.77K−4.3%13.1K after